Article: Nicotinamide Riboside Supplementation Does Not Disrupt Methylation, Including in Individuals with MTHFR Mutations: Clinical Findings

Mar 17, 2023 Clinical Neurological Health Parkinson's Disease

Nicotinamide Riboside Supplementation Does Not Disrupt Methylation, Including in Individuals with MTHFR Mutations: Clinical Findings

Objectives

To investigate the impact of NR supplementation on DNA methylation patterns in the blood cells and muscle tissues of newly diagnosed, dopaminergic treatment-naïve Parkinson's disease (PD) patients.

Journal

iScience

Key Outcomes

NR supplementation had no impact on DNA methylation in PD patients, including in those with common mutations in the MTHFR gene.
NR also resulted in minor changes in the activity of metabolic pathways and patterns of DNA methylation. However, these changes were not harmful and did not disrupt normal DNA methylation.

Duration

30 days

Dose

1000 mg

Study Design

Randomized, double-blind, placebo-controlled, phase I study in 29 newly diagnosed Parkinson's disease (PD) patients

See Published Study

Cancer

Nicotinamide Riboside Slows Liver Cancer Growth and Metastasis: Preclinical Findings

SynopsisNicotinamide adenine dinucleotide (NAD+) metabolism has emerged as a target in cancer treatment. This study evaluated the effects of nicotinamide riboside (NR), a NAD+ precursor, on hepatoc...